Gene Therapy for Heart Failure.
10.4070/kcj.2005.35.5.345
- Author:
Jang Whan BAE
1
;
Myeong Chan CHO
Author Information
1. Department of Internal Medicine, Chungbuk National University College of Medicine, Medical Research Institute, Chungbuk National University, Cheongju, Korea. mccho@cbnu.ac.kr
- Publication Type:Review
- Keywords:
Heart failure;
Gene therapy;
Vector
- MeSH:
Cardiovascular Diseases;
Developed Countries;
Genetic Therapy*;
Heart Failure*;
Heart*;
Survival Rate
- From:Korean Circulation Journal
2005;35(5):345-352
- CountryRepublic of Korea
- Language:English
-
Abstract:
Heart failure is an important public medical problem in the developed countries. Although there are numerous and fascinating medicines given by physicians for the treatment of heart failure, the general 5 year survival rate for advanced heart failure is only about 50%. There are still many theoretical and practical problems to overcome before the application of gene therapy to cardiovascular disease becomes a reality in the future. With our increased knowledge on the development of gene delivery, vector systems, molecular basis of cardiac dysfunction, and the pathogenesis of heart failure at the cell level, gene therapy is emerging as a new therapeutic option for heart failure.
